Search Results
910 results found-
As 2023 comes to a close, leaders in patient advocacy shared accomplishments and highlights in CSL.com’s annual survey.
https://www.csl.com/we-are-csl/vita-original-stories/2023/a-year-of-progress-for-patients -
CSL Behring's HAEGARDA, for the prevention of Hereditary Angioedema attacks, was approved by the US Food and Drug Administration in June 2017.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
The U.S. Hereditary Angioedema Association (HAEA) and HAE International (HAEi) offer fun, educational and empowering programming for kids and young adults with the rare genetic condition.
https://www.csl.com/we-are-csl/vita-original-stories/2023/hae-youth-programs-around-the-globe -
The pandemic changed the way patient communities connect, but it didn’t change their “I got your back” philosophy, according to advocates we surveyed.
https://www.csl.com/we-are-csl/vita-original-stories/2022/finding-community-in-2022 -
CSL Behring CSL Behring discovers, develops and delivers the broadest range of products in the industry for treating rare and serious diseases such as haemophilia, von Willebrand disease (vWD), primary and secondary immune deficiencies (PID/SID), chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE) and inherited respiratory disease.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
Watch It Online: CSL Behring's 'How It's Made'
https://www.csl.com/we-are-csl/vita-original-stories/2019/watch-it-online-csl-behring-how-its-made -
Few Australians understand how common rare diseases are, but 89% said it was important to research innovative new treatments, according to a new survey of 1,000 Australian adults.
https://www.csl.com/we-are-csl/vita-original-stories/2024/survey-how-much-do-australians-know-about-rare-diseases -
A new survey of more than 1,000 U.S. residents finds that few know how common rare diseases are, but 85% said it was important to research innovative new treatments.
https://www.csl.com/we-are-csl/vita-original-stories/2024/survey-how-much-do-us-residents-know-about-rare-diseases -
Pathogen expert Nathan Roth leads a team that takes a vigilant approach with the medicines patients rely on.
https://www.csl.com/we-are-csl/vita-original-stories/2019/pathogen-expert-nathan-roth